These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 31483485)

  • 1. Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.
    Higano CS; Armstrong AJ; Sartor AO; Vogelzang NJ; Kantoff PW; McLeod DG; Pieczonka CM; Penson DF; Shore ND; Vacirca J; Concepcion RS; Tutrone RF; Nordquist LT; Quinn DI; Kassabian V; Scholz MC; Harmon M; Tyler RC; Chang NN; Tang H; Cooperberg MR
    Cancer; 2019 Dec; 125(23):4172-4180. PubMed ID: 31483485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED Registry.
    Wei XX; Kwak L; Hamid A; He M; Sweeney C; Flanders SC; Harmon M; Choudhury AD
    Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):314-319. PubMed ID: 35145218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents.
    Hafron JM; Wilfehrt HM; Ferro C; Harmon M; Flanders SC; McKay RR
    Adv Ther; 2022 Jun; 39(6):2515-2532. PubMed ID: 35352309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry.
    Sartor O; Armstrong AJ; Ahaghotu C; McLeod DG; Cooperberg MR; Penson DF; Kantoff PW; Vogelzang NJ; Hussain A; Pieczonka CM; Shore ND; Quinn DI; Small EJ; Heath EI; Tutrone RF; Schellhammer PF; Harmon M; Chang NN; Sheikh NA; Brown B; Freedland SJ; Higano CS
    Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):517-526. PubMed ID: 32111923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer.
    McKay RR; Hafron JM; Ferro C; Wilfehrt HM; Fitch K; Flanders SC; Fabrizio MD; Schweizer MT
    Adv Ther; 2020 Dec; 37(12):4910-4929. PubMed ID: 33029725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy.
    Wei XX; Perry J; Chang E; Zhang L; Hiatt RA; Ryan CJ; Small EJ; Fong L
    Clin Genitourin Cancer; 2018 Jun; 16(3):184-190.e2. PubMed ID: 29352713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T.
    Small EJ; Higano CS; Kantoff PW; Whitmore JB; Frohlich MW; Petrylak DP
    Prostate Cancer Prostatic Dis; 2014 Sep; 17(3):259-64. PubMed ID: 24957547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer.
    Caram MEV; Ross R; Lin P; Mukherjee B
    JAMA Netw Open; 2019 Apr; 2(4):e192589. PubMed ID: 31002323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate-Resistant Prostate Cancer.
    Heath EI; Thakur A; Chen W; Hwang C; Paller CJ; Cackowski FC; Boerner JL; Heilbrun L; Smith MP; Schalk DL; Schienschang A; Whitaker SA; Polend A; Smith D; Vaishampayan UN; Dickow B; Lum LG
    Cancer Res Commun; 2024 Jul; 4(7):1715-1725. PubMed ID: 38856749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of abiraterone and sipuleucel-T in asymptomatic metastatic castration-resistant prostate cancer.
    Gong CL; Hay JW
    J Natl Compr Canc Netw; 2014 Oct; 12(10):1417-25. PubMed ID: 25313181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
    Loblaw DA; Walker-Dilks C; Winquist E; Hotte SJ;
    Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry.
    Chowdhury S; Bjartell A; Lumen N; Maroto P; Paiss T; Gomez-Veiga F; Birtle A; Kramer G; Kalinka E; Spaëth D; Feyerabend S; Matveev V; Lefresne F; Lukac M; Wapenaar R; Costa L
    Target Oncol; 2020 Jun; 15(3):301-315. PubMed ID: 32500294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer.
    Marshall CH; Fu W; Wang H; Park JC; DeWeese TL; Tran PT; Song DY; King S; Afful M; Hurrelbrink J; Manogue C; Cotogno P; Moldawer NP; Barata PC; Drake CG; Posadas EM; Armstrong AJ; Sartor O; Antonarakis ES
    Clin Cancer Res; 2021 Mar; 27(6):1623-1630. PubMed ID: 33451978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer.
    Twardowski P; Wong JYC; Pal SK; Maughan BL; Frankel PH; Franklin K; Junqueira M; Prajapati MR; Nachaegari G; Harwood D; Agarwal N
    Cancer Treat Res Commun; 2019; 19():100116. PubMed ID: 30682445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States.
    George DJ; Sartor O; Miller K; Saad F; Tombal B; Kalinovský J; Jiao X; Tangirala K; Sternberg CN; Higano CS
    Clin Genitourin Cancer; 2020 Aug; 18(4):284-294. PubMed ID: 32057714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sipuleucel-T for the Treatment of Metastatic Hormone-Relapsed Prostate Cancer: A NICE Single Technology Appraisal; An Evidence Review Group Perspective.
    Simpson EL; Davis S; Thokala P; Breeze PR; Bryden P; Wong R
    Pharmacoeconomics; 2015 Nov; 33(11):1187-94. PubMed ID: 26017401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.
    Small EJ; Lance RS; Gardner TA; Karsh LI; Fong L; McCoy C; DeVries T; Sheikh NA; GuhaThakurta D; Chang N; Redfern CH; Shore ND
    Clin Cancer Res; 2015 Sep; 21(17):3862-9. PubMed ID: 25925891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
    Di Lorenzo G; Ferro M; Buonerba C
    BJU Int; 2012 Jul; 110(2 Pt 2):E99-104. PubMed ID: 22177289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
    Bui CN; O'Day K; Flanders S; Oestreicher N; Francis P; Posta L; Popelar B; Tang H; Balk M
    J Manag Care Spec Pharm; 2016 Feb; 22(2):163-70. PubMed ID: 27015255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.
    Wei XX; Fong L; Small EJ
    Expert Rev Vaccines; 2015; 14(12):1529-41. PubMed ID: 26488270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.